BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28789475)

  • 1. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.
    Pratt D; Pittaluga S; Palisoc M; Fetsch P; Xi L; Raffeld M; Gilbert MR; Quezado M
    J Neuropathol Exp Neurol; 2017 Aug; 76(8):697-708. PubMed ID: 28789475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
    Ge H; Mu L; Jin L; Yang C; Chang YE; Long Y; DeLeon G; Deleyrolle L; Mitchell DA; Kubilis PS; Lu D; Qi J; Gu Y; Lin Z; Huang J
    Int J Cancer; 2017 Oct; 141(7):1434-1444. PubMed ID: 28612394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD70, a novel target of CAR T-cell therapy for gliomas.
    Jin L; Ge H; Long Y; Yang C; Chang YE; Mu L; Sayour EJ; De Leon G; Wang QJ; Yang JC; Kubilis PS; Bao H; Xia S; Lu D; Kong Y; Hu L; Shang Y; Jiang C; Nie J; Li S; Gu Y; Sun J; Mitchell DA; Lin Z; Huang J
    Neuro Oncol; 2018 Jan; 20(1):55-65. PubMed ID: 28651374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An IDH1-mutated primary gliosarcoma: case report.
    Hsieh JK; Hong CS; Manjila S; Cohen ML; Lo S; Rogers L; Sloan AE
    J Neurosurg; 2017 Feb; 126(2):476-480. PubMed ID: 27153165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.
    Smith DR; Wu CC; Saadatmand HJ; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; Wang SH; Canoll P; McKhann GM; Wang TJC
    J Neurooncol; 2018 Apr; 137(2):303-311. PubMed ID: 29264835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation of IDH-wildtype glioblastoma to gliosarcoma with features of osteosarcoma.
    Sobczyk P; Sobstyl M; Acewicz A; Rosa J; Grabiec M; Grajkowska W
    Folia Neuropathol; 2024; 62(1):96-101. PubMed ID: 38741436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
    Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
    Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.
    Cachia D; Kamiya-Matsuoka C; Mandel JJ; Olar A; Cykowski MD; Armstrong TS; Fuller GN; Gilbert MR; De Groot JF
    J Neurooncol; 2015 Nov; 125(2):401-10. PubMed ID: 26354773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
    Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.
    Rodriguez FJ; Scheithauer BW; Giannini C; Bryant SC; Jenkins RB
    Cancer; 2008 Nov; 113(10):2779-89. PubMed ID: 18816605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.
    Dardis C; Donner D; Sanai N; Xiu J; Mittal S; Michelhaugh SK; Pandey M; Kesari S; Heimberger AB; Gatalica Z; Korn MW; Sumrall AL; Phuphanich S
    BMC Neurol; 2021 Jun; 21(1):231. PubMed ID: 34162346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
    Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
    J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gliosarcoma: Neuroimaging and Immunohistochemical Findings.
    Peckham ME; Osborn AG; Palmer CA; Tsai A; Salzman KL
    J Neuroimaging; 2019 Jan; 29(1):126-132. PubMed ID: 30295979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations.
    Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL
    Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rare case of BRAF V600E-mutated epithelioid glioblastoma with a sarcomatous component.
    Ishikawa R; Kadota K; Hayashi T; Kimura N; Inoue K; Ibuki E; Kagawa S; Kushida Y; Okada M; Miyake K; Tamiya T; Nobusawa S; Hirato J; Haba R
    Pathol Int; 2020 Mar; 70(3):166-170. PubMed ID: 31903645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status.
    Roodakker KR; Elsir T; Edqvist PD; Hägerstrand D; Carlson J; Lysiak M; Henriksson R; Pontén F; Rosell J; Söderkvist P; Stupp R; Tchougounova E; Nistér M; Malmström A; Smits A
    Oncotarget; 2016 Nov; 7(45):72431-72442. PubMed ID: 27626492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD70 represents the human ligand for CD27.
    Hintzen RQ; Lens SM; Koopman G; Pals ST; Spits H; van Lier RA
    Int Immunol; 1994 Mar; 6(3):477-80. PubMed ID: 8186199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gliosarcoma in patients under 20 years of age. A clinicopathologic study of 11 cases and detailed review of the literature.
    Din NU; Ishtiaq H; Rahim S; Abdul-Ghafar J; Ahmad Z
    BMC Pediatr; 2021 Feb; 21(1):101. PubMed ID: 33637068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain.
    Geisenberger C; Mock A; Warta R; Rapp C; Schwager C; Korshunov A; Nied AK; Capper D; Brors B; Jungk C; Jones D; Collins VP; Ichimura K; Bäcklund LM; Schnabel E; Mittelbron M; Lahrmann B; Zheng S; Verhaak RG; Grabe N; Pfister SM; Hartmann C; von Deimling A; Debus J; Unterberg A; Abdollahi A; Herold-Mende C
    Acta Neuropathol; 2015 Sep; 130(3):419-34. PubMed ID: 25931051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.